Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

Andrea Necchi*, Mathieu Roumiguié, Ashish M. Kamat, Neal D. Shore, Joost L. Boormans, Ahmet Adil Esen, Thierry Lebret, Shuya Kandori, Dean F. Bajorin, Laurence E.M. Krieger, Scot A. Niglio, Edward M. Uchio, Ho Kyung Seo, Ronald de Wit, Eric A. Singer, Petros Grivas, Hiroyuki Nishiyama, Haojie Li, Pranshu Baranwal, Margot Van den Sigtenhorst-FijlstraEkta Kapadia, Girish S. Kulkarni

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science